Edgewise Therapeutics (EWTX) announced that on December 31, 2025, Edgewise granted inducement stock options to purchase a total of 119,250 shares of Edgewise’s common stock to 4 new non-executive employees in connection with the commencement of their employment, pursuant to Edgewise’s 2024 Inducement Equity Incentive Plan.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EWTX:
- Edgewise Therapeutics: Advancing EDG-7500 in Hypertrophic Cardiomyopathy Underpins Buy Rating and Future Value Catalysts
- Edgewise Therapeutics rises 20.3%
- Edgewise Therapeutics: Differentiated EDG-7500 Profile, Late-Stage Cardiology Catalyst, and Expanding Pipeline Support Buy Rating
- H.C. Wainwright says Edgewise data reinforces EDG-7500 potential differentiation
- Prolonged Safety Uncertainty and Eroding Differentiation Keep EDG-7500 at Hold